Search research articles
Contact Us
Filters
Showing results (91-100 of 121) with videos related to
Page
of 13
Sort By:
Diabetes Care
|
January 3, 2012
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study
David Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, et al.
BMC Nephrology
|
November 20, 2014
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study
Luis Ruilope, Markolf Hanefeld, A Michael Lincoff, et al.
Journal of Diabetes and Its Complications
|
March 22, 2014
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
Julio Rosenstock, Markolf Hanefeld, Paramesh Shamanna, et al.
Cardiovascular Diabetology
|
April 26, 2008
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)
Michel Komajda, Paula Curtis, Markolf Hanefeld, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 8, 2018
Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol
Christoph Schindler, Andreas L Birkenfeld, Markolf Hanefeld, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
November 15, 2017
Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol
Christoph Schindler, Andreas L Birkenfeld, Markolf Hanefeld, et al.
Diabetes Care
|
February 15, 2008
Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia
Zvonko Milicevic, Itamar Raz, Scott D Beattie, et al.
The New England Journal of Medicine
|
June 7, 2007
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis
Philip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
Diabetes Care
|
April 20, 2017
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035
Julio Rosenstock, Ronnie Aronson, George Grunberger, et al.
European Journal of Heart Failure
|
September 15, 2012
Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?
Anselm K Gitt, Martin Halle, Markolf Hanefeld, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 121) with videos related to
Sort By:
Page
of 13
Diabetes Care
|
January 3, 2012
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study
David Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, et al.
BMC Nephrology
|
November 20, 2014
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study
Luis Ruilope, Markolf Hanefeld, A Michael Lincoff, et al.
Journal of Diabetes and Its Complications
|
March 22, 2014
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
Julio Rosenstock, Markolf Hanefeld, Paramesh Shamanna, et al.
Cardiovascular Diabetology
|
April 26, 2008
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)
Michel Komajda, Paula Curtis, Markolf Hanefeld, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 8, 2018
Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol
Christoph Schindler, Andreas L Birkenfeld, Markolf Hanefeld, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
November 15, 2017
Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol
Christoph Schindler, Andreas L Birkenfeld, Markolf Hanefeld, et al.
Diabetes Care
|
February 15, 2008
Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia
Zvonko Milicevic, Itamar Raz, Scott D Beattie, et al.
The New England Journal of Medicine
|
June 7, 2007
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis
Philip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
Diabetes Care
|
April 20, 2017
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035
Julio Rosenstock, Ronnie Aronson, George Grunberger, et al.
European Journal of Heart Failure
|
September 15, 2012
Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?
Anselm K Gitt, Martin Halle, Markolf Hanefeld, et al.
Page
of 13